Sagimet Biosciences Inc. Series A Common Stock
SGMTSagimet Biosciences Inc. Series A (SGMT) is a biotechnology company focused on developing innovative therapies for metabolic and fibrotic diseases. The company specializes in targeting liver and metabolic disorders through novel small molecule drugs, aiming to address unmet medical needs in these areas.
Company News
Sagimet Biosciences reported positive Phase 3 clinical trial results for denifanstat in treating moderate to severe acne in China, with the drug meeting all primary and secondary endpoints and being well-tolerated.
Sagimet Biosciences reported positive Phase 3 clinical trial results for denifanstat, a novel oral medication for treating moderate to severe acne, with significant improvements in lesion reduction and treatment success rates.
Sagimet Biosciences will present two oral presentations at the 9th Annual MASH Drug Development Summit, focusing on their FASN inhibitor denifanstat and its potential treatment for metabolic dysfunction associated steatohepatitis (MASH).
Sagimet Biosciences will participate in the Canaccord Genuity Growth Conference and has completed a successful Phase 2b clinical trial for denifanstat in treating metabolic dysfunction associated steatohepatitis (MASH). The company has also initiated a Phase 1 trial for a new FASN inhibitor targeting acne treatment.
Sagimet Biosciences announced positive Phase 3 results for its acne drug denifanstat, which met all primary and secondary endpoints versus placebo and was well-tolerated. The company also discussed plans for a first-in-human study of a second oral FASN inhibitor drug candidate, TVB-3567, for acne.
